TuHURA Biosciences Files 8-K for Material Agreement
Ticker: HURA · Form: 8-K · Filed: Sep 11, 2025 · CIK: 1498382
Sentiment: neutral
Topics: material-agreement, corporate-actions, filing
TL;DR
TuHURA Bio entered a material agreement on 9/5, filed 8-K 9/11.
AI Summary
TuHURA Biosciences, Inc. (formerly Kintara Therapeutics, Inc.) filed an 8-K on September 11, 2025, reporting a material definitive agreement entered into on September 5, 2025. The filing also includes financial statements and exhibits. The company is incorporated in Nevada and its principal executive offices are located in Tampa, Florida.
Why It Matters
This 8-K filing indicates TuHURA Biosciences has entered into a significant agreement, which could impact its business operations, strategic direction, and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided filing excerpt.
Key Numbers
- 001-37823 — SEC File Number (Identifies the company's filing history with the SEC.)
- 99-0360497 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- TuHURA Biosciences, Inc. (company) — Registrant
- Kintara Therapeutics, Inc. (company) — Former company name
- DelMar Pharmaceuticals, Inc. (company) — Former company name
- Berry Only Inc. (company) — Former company name
- September 5, 2025 (date) — Date of earliest event reported
- September 11, 2025 (date) — Date of report
- Nevada (jurisdiction) — State of incorporation
- Tampa, Florida (location) — Principal executive offices
FAQ
What is the nature of the material definitive agreement entered into by TuHURA Biosciences?
The provided excerpt does not specify the details of the material definitive agreement, only that one was entered into on September 5, 2025.
When was TuHURA Biosciences, Inc. formerly known as Kintara Therapeutics, Inc.?
The date of the name change from Kintara Therapeutics, Inc. to TuHURA Biosciences, Inc. was August 20, 2020.
Where are TuHURA Biosciences, Inc.'s principal executive offices located?
The principal executive offices are located at 10500 University Center Dr., Suite 110, Tampa, Florida 33612.
What is the Standard Industrial Classification (SIC) code for TuHURA Biosciences, Inc.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
What items are being reported in this 8-K filing?
This 8-K filing reports on the 'Entry into a Material Definitive Agreement' and 'Financial Statements and Exhibits'.
Filing Stats: 760 words · 3 min read · ~3 pages · Grade level 11.6 · Accepted 2025-09-11 16:30:27
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share HURA The Nasdaq
- $3.3125 — of Common Stock at an exercise price of $3.3125 (the "Warrants"), for an aggregate offe
- $12.6 million — regate offering amount of approximately $12.6 million. The combined effective offering price
- $2.65 — ccompanying Warrant in the Offering was $2.65. In addition to the approximately $8.
- $8.9 million — .65. In addition to the approximately $8.9 million that was purchased in four tranches thr
- $3.7 million — ities Purchase Agreement, approximately $3.7 million of the Offering (the "Final Tranche Off
- $3.2 million — to immediately purchase an aggregate of $3.2 million of the Final Tranche Offering Amount in
Filing Documents
- hura-20250905.htm (8-K) — 51KB
- hura-ex10_1.htm (EX-10.1) — 13KB
- hura-ex10_2.htm (EX-10.2) — 49KB
- 0000950170-25-114235.txt ( ) — 233KB
- hura-20250905.xsd (EX-101.SCH) — 30KB
- hura-20250905_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. As previously announced, on June 2, 2025, TuHURA Biosciences, Inc. (the "Company") and investors (the "Purchasers") entered into a securities purchase agreement (the "Securities Purchase Agreement") pursuant to which the Company agreed to issue to the Purchasers, in a private placement (the "Offering"), an aggregate of 4.76 million shares (the "Shares") of the Company's common stock, par value $0.001 per share ("Common Stock"), together with warrants to purchase an equal number of shares of Common Stock at an exercise price of $3.3125 (the "Warrants"), for an aggregate offering amount of approximately $12.6 million. The combined effective offering price for each Share and accompanying Warrant in the Offering was $2.65. In addition to the approximately $8.9 million that was purchased in four tranches through July 24, 2025, under the Securities Purchase Agreement, approximately $3.7 million of the Offering (the "Final Tranche Offering Amount") was required under the Securities Purchase Agreement to be purchased and funded by December 31, 2025 by four Purchasers who had the right defer the purchase of a portion of their Common Stock and Warrants until such time (the "Deferral Investors"). The Deferral Investors were Pranabio Investments LLC, Garden Street House, LLC, Thomas C. Mollick, and Matthew Nachtrab. On September 5, 2025, each of Deferral Investors and the Company entered into an agreement (the "Final Purchase Agreements") pursuant to which they agreed to immediately purchase an aggregate of $3.2 million of the Final Tranche Offering Amount in exchange for the Company's agreement, set forth in a Warrant Amendment Agreement between the Company and each Deferral Investor (the "Warrant Amendment Agreements"), to extend the expiration dates of certain warrants to purchase an aggregate of 1.5 million shares of Company common stock that were issued by the Company's predecessor in a 2024 private placement of c
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No 10.1 Form of Final Closing Agreement. 10.2 Form of Warrant Amendment Agreement. 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TUHURA BIOSCIENCES, INC. Date: September 11, 2025 By: /s/ Dan Dearborn Name: Dan Dearborn Title: Chief Financial Officer